This handout is for acute hf — takotsubo (apical ballooning) decompensation (non-shock). Your care team identified this based on: bedside echo: apical ballooning (or atypical pattern: midventricular, basal, focal) + lv systolic dysfunction + congestion but preserved perfusion (sbp ≥90 + lactate <2) → takotsubo adhf non-shock spectrum.
Other reasons your team may use this plan: recent emotional (death of loved one, divorce, financial loss) or physical (surgery, severe illness, sepsis recovery) stressor in postmenopausal female (~90% predominance) presenting with new hf symptoms without shock; chest pain or new dyspnea + diffuse t-wave inversion + qt prolongation on ecg + lv dysfunction on echo + modest troponin rise (disproportionate to lv dysfunction); markedly elevated nt-probnp (often >3000) with disproportionately modest troponin rise + new lv dysfunction — classical takotsubo discordance pattern.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| furosemide | 40-80 mg IV (diuretic-naive); 2.5x outpatient PO dose IV if on chronic loop (DOSE-trial guided) | IV | q12h titrate to UOP | DOSE PMID 21366472 — titrate to UOP + symptom resolution; AVOID in LVOT-obstruction subtype (preload-dependent physiology); transition to PO before discharge |
| nitroglycerin | 5-20 µg/min IV titrate | IV | continuous | Preload + modest afterload reduction for hypertensive ADHF; AVOID in LVOT-obstruction subtype (preload reduction worsens dynamic gradient); avoid if SBP <100 |
| esmolol | 500 µg/kg bolus then 50-200 µg/kg/min | IV | continuous, titrate | LVOT-obstruction Takotsubo subset (15-25%) — β-blocker reduces dynamic gradient and improves forward flow; esmolol short-acting allows rapid titration; AVOID in non-LVOT subtype during acute catecholamine surge |
| phenylephrine | 40-360 µg/min IV | IV | continuous | Pure α-agonist; preferred in LVOT-obstruction subtype because raises afterload without inotropy (which worsens dynamic obstruction); ESC HFA 2016 Lyon position |
| carvedilol | 3.125 mg PO BID titrate (initiate AS LV recovers + off catecholamine excess + no LVOT obstruction) | PO | BID | CAPRICORN PMID 11356436 — but Lyon 2016 ESC HFA position cautions against acute initiation during catecholamine surge; introduce as LV recovers; debated long-term role per InterTAK protocols |
| lisinopril | 5 mg PO daily titrate to 10-40 mg | PO | daily | Lyon 2016 ESC HFA position + modified InterTAK protocols — initiate during recovery for residual LV dysfunction; standard ADHF afterload reduction; AVOID during acute catecholamine surge if hypotensive |
| losartan | 25-50 mg PO daily | PO | daily | ARB alternative if ACEi cough or angioedema; same LV reverse-remodeling rationale during Takotsubo recovery |
| spironolactone | 12.5-25 mg PO daily | PO | daily | RALES PMID 10471456 extrapolated — modified InterTAK protocols suggest case-by-case use during recovery if persistent EF <40; debated for typical Takotsubo (recovery is the rule) |
| warfarin | 5 mg PO daily INR target 2-3 | PO | daily × 3 mo | AHA 2022 Class IIa for LV thrombus (extrapolated to Takotsubo) — apical-ballooning Takotsubo carries mural-thrombus risk while LV remains dysfunctional; 3-mo course typically sufficient given recovery timeline; INR monitoring |
| apixaban | 5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) | PO | BID × 3 mo for mural-thrombus prophylaxis | Off-label-but-rational DOAC alternative for LV thrombus prophylaxis; small RCTs (NoT-DAPT, Xarelto LV-thrombus) support non-inferiority to warfarin in LV thrombus prevention; 3-mo course |
| magnesium sulfate | 2 g IV over 15-20 min for active torsades; 1-2 g IV q4-6h for prophylactic K/Mg replacement | IV | as needed for QT/torsades | Standard QT prolongation + torsades management; Takotsubo QT typically resolves with LV recovery; aggressive K replacement to ≥4 + Mg to ≥2 |
Plan: Takotsubo (apical ballooning) ADHF non-shock — supportive ADHF + AVOID INOTROPES + cautious BB (non-LVOT) or REQUIRED BB (LVOT subset) + LVOT-aware fluid/vasopressor strategy + mural-thrombus prophylaxis (Templin NEJM 2015 PMID 26332547; Ghadri 2018 InterTAK PMID 29850871; Lyon 2016 ESC HFA PMID 26890206; AHA 2024 Wright PMID 38258576)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cardiology follow-up at 1-2 wks + 4-8 wks (recovery echo) + 3 mo + 6 mo + 12 mo; recovery echo at 4-8 wks confirms complete LV recovery typical (Templin PMID 26332547); discontinue mural-thrombus AC at 3 mo if EF normalized + apical akinesia resolved per AHA 2022 LV thrombus consensus; long-term ARNI/BB after recovery debated case-by-case (no RCT-grade evidence — Lyon 2016 ESC HFA position); psychiatry follow-up if emotional trigger; recurrence ~5-10% lifetime — patient education on stressor mitigation; cardiac MRI at 4-8 wks for LGE persistence assessment if initial atypical pattern
Guideline: InterTAK consortium / Ghadri 2018 Eur Heart J expert consensus Part I + II (PMID 29850871 + 29850820); Templin NEJM 2015 PMID 26332547 (InterTAK registry); Lyon 2016 ESC HFA position statement on Takotsubo (PMID 26890206); 2022 ACC/AHA HF Guideline (PMID 35363499); AHA scientific statement on Takotsubo (Wright Circulation 2024 PMID 38258576)